PFSA (Profusa) Notes Receivable: $0.00 Mil (As of Mar. 2026)


PFSA Profusa Inc PFSA
8 GF Score
Price $2.10
! 3 Warning Signs
View Full Analysis

What is Profusa Notes Receivable?

Profusa PFSA -16.54% 8 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Profusa's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Profusa Notes Receivable Historical Data

* Premium members only.

The historical data trend for Profusa's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profusa Notes Receivable Chart

Profusa Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Profusa Quarterly Data
Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PFSA
8GF Score
Profusa Inc PFSA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Profusa Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Profusa (PFSA) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Profusa and its competitors.
Is Profusa's Notes Receivable too high?
Profusa's current Notes Receivable is $0.00 Mil. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's Notes Receivable compare to ODYY and SSKN?
Profusa's Notes Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Profusa and its competitors. Profusa's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Profusa (PFSA), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Profusa Business Description

Address 626 Bancroft Way, Suite A, Berkeley, CA, USA, 94710
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score

Get the complete analysis for PFSA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price